Xponance Inc. Increases Position in Solventum Co. (NYSE:SOLV)

Xponance Inc. increased its stake in Solventum Co. (NYSE:SOLV) by 9.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,014 shares of the company’s stock after purchasing an additional 1,879 shares during the quarter. Xponance Inc.’s holdings in Solventum were worth $1,388,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Hotchkis & Wiley Capital Management LLC purchased a new position in Solventum during the 3rd quarter valued at about $125,488,000. Trian Fund Management L.P. increased its holdings in Solventum by 32.9% during the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after acquiring an additional 1,765,676 shares in the last quarter. Boston Partners purchased a new position in Solventum during the 4th quarter valued at about $110,378,000. Point72 Asset Management L.P. purchased a new position in Solventum during the 3rd quarter valued at about $50,948,000. Finally, Nordea Investment Management AB increased its holdings in Solventum by 189.5% during the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock valued at $43,902,000 after acquiring an additional 431,986 shares in the last quarter.

Solventum Price Performance

SOLV opened at $74.00 on Friday. The company’s 50 day simple moving average is $75.17 and its 200 day simple moving average is $71.56. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The stock has a market capitalization of $12.80 billion and a PE ratio of 26.91.

Analysts Set New Price Targets

Several research firms have weighed in on SOLV. Bank of America raised their target price on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. The Goldman Sachs Group raised their target price on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. Wells Fargo & Company raised their target price on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Piper Sandler raised their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Finally, Morgan Stanley raised their price target on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Solventum has an average rating of “Hold” and an average target price of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.